NASDAQ:MGTX MeiraGTx Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. $7.31 -0.23 (-3.05%) (As of 06/28/2022 02:30 PM ET) Add Compare Share Today's Range$7.09▼$7.5350-Day Range$6.80▼$12.8852-Week Range$6.59▼$24.89Volume6,722 shsAverage Volume139,689 shsMarket Capitalization$326.83 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTX Stock Forecast (MarketRank)Overall MarketRank™2.62 out of 5 starsMedical Sector83rd out of 1,436 stocksBiological Products, Except Diagnostic Industry12th out of 217 stocksAnalyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingMeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, MeiraGTx has a forecasted upside of 312.1% from its current price of $7.28.Amount of Analyst CoverageMeiraGTx has only been the subject of 1 research reports in the past 90 days. Previous Next 4.8 Community Rank Outperform VotesMeiraGTx has received 182 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMeiraGTx has received 73 “underperform” votes. (Add your “underperform” vote.)Community SentimentMeiraGTx has received 71.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote “Outperform” if you believe MGTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMeiraGTx does not currently pay a dividend.Dividend GrowthMeiraGTx does not have a long track record of dividend growth. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MeiraGTx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $47,440.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.30% of the stock of MeiraGTx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.68% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MeiraGTx are expected to grow in the coming year, from ($2.33) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MeiraGTx is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MeiraGTx is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMeiraGTx has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MeiraGTx (NASDAQ:MGTX)MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.Read More MGTX Stock News HeadlinesJune 28, 2022 | streetinsider.comMeiraGTx Holdings plc (MGTX) Reports Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision - StreetInsider.comJune 28, 2022 | globenewswire.comMeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) co - GlobeNewswireJune 16, 2022 | finance.yahoo.comFurther weakness as MeiraGTx Holdings (NASDAQ:MGTX) drops 13% this week, taking three-year losses to 67%June 7, 2022 | americanbankingnews.comMeiraGTx Holdings plc (NASDAQ:MGTX) Insider Robert K. Zeldin Buys 5,000 SharesMay 13, 2022 | benzinga.comBarclays Maintains Overweight on MeiraGTx Hldgs, Lowers Price Target to $18 - Benzinga - BenzingaMay 13, 2022 | benzinga.comMeiraGTx Hldgs: Q1 Earnings Insights - Benzinga - BenzingaMay 12, 2022 | finance.yahoo.comMeiraGTx Reports First Quarter 2022 Financial and Operational Results - Yahoo FinanceMay 12, 2022 | finance.yahoo.comMeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2022 | globenewswire.comMeiraGTx Reports First Quarter 2022 Financial and Operational Results - GlobeNewswireMay 12, 2022 | finance.yahoo.comMeiraGTx Reports First Quarter 2022 Financial and Operational ResultsMay 10, 2022 | finance.yahoo.comCompanies Like MeiraGTx Holdings (NASDAQ:MGTX) Are In A Position To Invest In GrowthMay 9, 2022 | nasdaq.comKrystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates - NasdaqMay 6, 2022 | finance.yahoo.comMeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting - Yahoo FinanceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGTX CUSIPN/A CIK1735438 Webwww.meiragtx.com Phone(646) 860-7985FaxN/AEmployees287Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/28/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$30.00 High Stock Price Forecast$46.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+310.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.970010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79.56 million Net Margins-224.55% Pretax Margin-224.55% Return on Equity-47.01% Return on Assets-28.11% Debt Debt-to-Equity Ratio0.13 Current Ratio2.18 Quick Ratio2.18 Sales & Book Value Annual Sales$37.70 million Price / Sales8.67 Cash FlowN/A Price / Cash FlowN/A Book Value$4.17 per share Price / Book1.75Miscellaneous Outstanding Shares44,710,000Free Float38,764,000Market Cap$326.83 million OptionableNot Optionable Beta1.84 MeiraGTx Frequently Asked Questions Should I buy or sell MeiraGTx stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MeiraGTx stock. View analyst ratings for MeiraGTx or view top-rated stocks. What is MeiraGTx's stock price forecast for 2022? 2 equities research analysts have issued twelve-month price objectives for MeiraGTx's stock. Their MGTX stock forecasts range from $18.00 to $46.00. On average, they predict MeiraGTx's stock price to reach $30.00 in the next year. This suggests a possible upside of 310.4% from the stock's current price. View analysts' price targets for MeiraGTx or view top-rated stocks among Wall Street analysts. How has MeiraGTx's stock price performed in 2022? MeiraGTx's stock was trading at $23.74 at the start of the year. Since then, MGTX stock has decreased by 69.2% and is now trading at $7.31. View the best growth stocks for 2022 here. When is MeiraGTx's next earnings date? MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for MeiraGTx. How were MeiraGTx's earnings last quarter? MeiraGTx Holdings plc (NASDAQ:MGTX) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.21. The firm had revenue of $5.63 million for the quarter, compared to the consensus estimate of $9.25 million. MeiraGTx had a negative trailing twelve-month return on equity of 47.01% and a negative net margin of 224.55%. View MeiraGTx's earnings history. Who are MeiraGTx's key executives? MeiraGTx's management team includes the following people: Dr. Alexandria Forbes, CEO, Pres & Director (Age 57, Pay $3.05M) (LinkedIn Profile)Mr. Richard Brian Giroux B.A., COO & CFO (Age 48, Pay $2.39M)Dr. Robert K. Zeldin M.D., Chief Medical Officer (Age 59, Pay $1.1M)Mr. Robert J. Wollin J.D., Gen. Counsel & Sec. (Age 45)Dr. Stuart Naylor Ph.D., Chief Devel. Officer (Age 59)Dr. Michel Michaelides M.D., Head of Clinical OphthalmologyMs. Christine Elise Sheehy, Sr. VP of Global Integration (Age 54)Mr. Joel P. Brooks, Sr. VP of Fin. (Age 63)Mr. Tim Randall, Sr. VP of Risk & Internal ControlsDr. Alastair Leighton Ph.D., Sr. VP of Manufacturing & Supply Chain Who are some of MeiraGTx's key competitors? Some companies that are related to MeiraGTx include Revolution Medicines (RVMD), SpringWorks Therapeutics (SWTX), Vaxcyte (PCVX), Adaptive Biotechnologies (ADPT), Sana Biotechnology (SANA), Vericel (VCEL), REGENXBIO (RGNX), Kymera Therapeutics (KYMR), Editas Medicine (EDIT), Alector (ALEC), Replimune Group (REPL), Arcellx (ACLX), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE) and iTeos Therapeutics (ITOS). View all of MGTX's competitors. What other stocks do shareholders of MeiraGTx own? Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD). When did MeiraGTx IPO? (MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager. What is MeiraGTx's stock symbol? MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX." Who are MeiraGTx's major shareholders? MeiraGTx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Royce & Associates LP (1.47%), State Street Corp (1.20%), Rhenman & Partners Asset Management AB (1.12%), Dimensional Fund Advisors LP (0.90%), Prosight Management LP (0.85%) and Assenagon Asset Management S.A. (0.67%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Robert J Wollin, Robert K Zeldin, Stuart Naylor and Thomas E Shenk. View institutional ownership trends for MeiraGTx. Which institutional investors are selling MeiraGTx stock? MGTX stock was sold by a variety of institutional investors in the last quarter, including Captrust Financial Advisors, Royce & Associates LP, Salem Investment Counselors Inc., UBS Group AG, TD Asset Management Inc., Jane Street Group LLC, Citigroup Inc., and Northern Trust Corp. Company insiders that have sold MeiraGTx company stock in the last two years include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Richard Giroux, Stuart Naylor, and Thomas E Shenk. View insider buying and selling activity for MeiraGTx or view top insider-selling stocks. Which institutional investors are buying MeiraGTx stock? MGTX stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Assenagon Asset Management S.A., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Alyeska Investment Group L.P., Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., and Bank of America Corp DE. Company insiders that have bought MeiraGTx stock in the last two years include Robert J Wollin, and Robert K Zeldin. View insider buying and selling activity for MeiraGTx or or view top insider-buying stocks. How do I buy shares of MeiraGTx? Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MeiraGTx's stock price today? One share of MGTX stock can currently be purchased for approximately $7.31. How much money does MeiraGTx make? MeiraGTx (NASDAQ:MGTX) has a market capitalization of $326.83 million and generates $37.70 million in revenue each year. The company earns $-79.56 million in net income (profit) each year or ($1.970010) on an earnings per share basis. How many employees does MeiraGTx have? MeiraGTx employs 287 workers across the globe. How can I contact MeiraGTx? MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The official website for MeiraGTx is www.meiragtx.com. The company can be reached via phone at (646) 860-7985 or via email at [email protected]. This page (NASDAQ:MGTX) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here